medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2024, Number 4

<< Back Next >>

Acta Med 2024; 22 (4)

Prevalence of fatty liver disease associated with metabolic dysfunction in the Hospital Angeles Pedregal over a three-year period

Gallegos GAC, Bautista MB, García ARS, Santibañez SV, Díaz GEJ

Language: Spanish
References: 18
Page: 281-285
PDF size: 286.48 Kb.


ABSTRACT

Introduction: metabolic dysfunction-associated fatty liver disease (MAFLD) is the most common cause of chronic liver disease. In Mexico, an estimated prevalence of 14.4% is diagnosed through ultrasound. Liver biopsy serves as the gold standard for diagnosis, defining hepatic steatosis as the accumulation of triglycerides in the hepatocyte cytoplasm. Objective: the present study aimed to determine the prevalence of steatohepatitis, fibrosis, and liver cirrhosis in a private hospital in Mexico City. Material and methods: an observational, retrospective, cross-sectional, and descriptive study was conducted, reviewing a database of 67 liver biopsies at Hospital Angeles del Pedregal Pathology Department from January 2021 to December 2023. Results: among the analyzed liver biopsies, 44.77% exhibited steatohepatitis. Of these, 50% were grade I, 30% were grade II, and 10% were grades III and IV, respectively. Fibrosis was present in 53.73% of patients (n = 36), from which 27.77% were grade 1, 11.11% grade 2, 11.11% grade 3, and 50% were grade 4, also categorized as cirrhosis. Conclusions: MAFLD is the most common cause of chronic liver disease and is the leading cause of liver disease-related morbidity and mortality in Mexico. The high prevalence of steatohepatitis, fibrosis, and cirrhosis in the present study demonstrates the importance of its timely diagnosis and prevention to ensure a better quality of life for patients.


REFERENCES

  1. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2023; 78 (6): 1966-1986. doi: 10.1097/hep.0000000000000520.

  2. Romero-Gómez M. Non-alcoholic steatohepatitis. Med Clin (Barc). 2022; 159 (8): 388-395. doi: 10.1016/j.medcli.2022.06.017.

  3. Chan WK, Chuah KH, Rajaram RB, Lim LL, Ratnasingam J, Vethakkan SR. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): a state-of-the-art review. J Obes Metab Syndr. 2023; 32 (3): 197-213. doi: 10.7570/jomes23052

  4. Flores YN, Amoon AT, Su B, Velazquez-Cruz R, Ramírez-Palacios P, Salmerón J et al. Serum lipids are associated with nonalcoholic fatty liver disease: a pilot case-control study in Mexico. Lipids Health Dis. 2021; 20 (1): 136. doi: 10.1186/s12944-021-01526-5.

  5. Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022; 22 (1): 63. doi: 10.1186/s12902-022-00980-1.

  6. Velarde-Ruiz VJA, García-Jiménez ES, García-Zermeño KR, Morel-Cerda EC, Aldana-Ledesma JM, Castro-Narro GE et al. Complicaciones extrahepáticas de la enfermedad por hígado graso no alcohólico: impacto más allá del hígado. Rev Gastroenterol Mex. 2019; 84 (4): 472-481. doi: 10.1016/j.rgmx.2019.05.004.

  7. Caro-Sabido EA, Larrosa-Haro A. Eficacia de la intervención nutricia y de la actividad física en niños y adolescentes con hígado graso no alcohólico asociado a obesidad: revisión sistemática exploratoria. Rev Gastroenterol Mex. 2019; 84 (2): 185-194. Disponible en: https://www.sciencedirect.com/science/article/pii/S0375090619300199

  8. Li AA, Ahmed A, Kim D. Extrahepatic manifestations of nonalcoholic fatty liver disease. Gut Liver. 2020; 14 (2): 168-178. doi: 10.5009/gnl19069.

  9. Henry ZH, Argo CK. How to identify the patient with nonalcoholic steatohepatitis who will progress to cirrhosis. Gastroenterol Clin North Am. 2020; 49 (1): 45-62. doi: 10.1016/j.gtc.2019.09.002.

  10. Caballeria L, Torán P. "Epidemia de esteatosis hepática: un análisis desde la atención primaria". Aten Primaria. 2019; 51 (9): 525-526. doi: 10.1016/j.aprim.2019.09.002.

  11. Flores YN, Amoon AT, Su B, Velazquez-Cruz R, Ramírez-Palacios P, Salmerón J et al. Serum lipids are associated with nonalcoholic fatty liver disease: a pilot case-control study in Mexico. Lipids Health Dis. 2021; 20 (1): 136. doi: 10.1186/s12944-021-01526-5.

  12. Bernal-Reyes R, Castro-Narro G, Malé-Velázquez R, Carmona-Sánchez R, González-Huezo MS, García-Juárez I et al. Consenso mexicano de la enfermedad por hígado graso no alcohólico. Rev Gastroenterol Mex. 2019; 84 (1): 69-99. doi: 10.1016/j.rgmx.2018.11.007.

  13. Saiman Y, Duarte-Rojo A, Rinella ME. Fatty liver disease: diagnosis and stratification. Annu Rev Med. 2022; 73 (1): 529-544. doi: 10.1146/annurev-med-042220-020407.

  14. Lin S, Huang J, Wang M, Kumar R, Liu Y, Liu S et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int. 2020; 40 (9): 2082-2089. doi: 10.1111/liv.14548.

  15. Ackerman LV, Rosai J. Capítulo 13: Hígado. In: Rosai y Ackerman Patología Quirúrgica. 10ma ed. Ciudad de México: Amolca; 2013. 878-883 p.

  16. Powell EE, Wong VWS, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021; 397 (10290): 2212-2224. doi: 10.1016/s0140-6736(20)32511-3.

  17. Graffigna M, Catoira N, Soutelo J, Azpelicueta A, Berg G, Perel C et al. Diagnóstico de esteatosis hepática por métodos clínicos, bioquímicos y por imágenes. Rev Argent Endocrinol Metab. 2017; 54 (1): 37-46. doi: 10.1016/j.raem.2016.12.001.

  18. Papatheodoridi M, Cholongitas E. Diagnosis of non-alcoholic fatty liver disease (NAFLD): current concepts. Curr Pharm Des. 2019; 24 (38): 4574-4586. doi: 10.2174/1381612825666190117102111.




2020     |     www.medigraphic.com